

RISHI TECHTEX LIMITED



RISHI TECHTEX

Registered Office : 612, Veena Killedar Industrial Estate, 10-14, Pais Street, Byculla (W), Mumbai - 400 011.
Tel. No. : 022-23075677, 23074897 Fax : 91 (22) 23080022 E-mail : info@rishitechtex.com
Website : www.rishitechtex.com CIN - L28129MH1984PLC032008

The Dy. General Manager,
Corporate Relations Department
Stock Exchange,
Mumbai

06.10.2020

Ref: Script Code-523021
ISIN: INE989D01010

Sub: Publication of Notice

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published Newspaper Advertisement regarding Notice of 36th Annual General Meeting, information on Remote E-voting, Book Closure and Record Date in 'Business Standard (English)' (Page No. 4) and 'Navakal (Marathi)' (Page No. 5) on Tuesday, 6th October, 2020.

The cuttings of Newspaper Advertisements are enclosed herewith for your reference and records.

Thanking You

Yours faithfully

For Rishi Techtex Limited

Gauri Gangal
Company Secretary

गौरी प्रदन वा दाका असल्यास सधामद
काठ किंवा ०२२-२३०८५४२/४३ येथे
गिरी टेक्स्टायल लि. करिता
सही/-
गौरी रांगरा
कांपनी संचालक

Indigenous players slow & steady in Covid vaccine race

Vaccine candidates from Hester Biosciences, Premas Biotech, Neuberg Supratech making progress

SOHINI DAS & VINAY KUMAR
Mumbai/Medical, 5 October

While leading vaccine candidates are in advanced stages of clinical trials, a handful of indigenous players, too, are progressing slowly, albeit steadily.

Not only do these players feel there will be room for multiple Covid-19 vaccines in the market, but they may also play a crucial role in scaling up national production of the successful candidate.

The country's largest veterinary vaccine maker Hester Biosciences, for example, is forgoing into the animal vaccine space with its Covid-19 vaccine candidate. It is developing the vaccine in collaboration with the Indian Institute of Technology (IIT)-Guwahati.


The vaccine will be based on an avian virus-based vector platform (avian paramyxovirus). Rajiv D Gandhi, managing director (MD) and chief executive officer (CEO), Hester Biosciences, said the firm had taken up space for a laboratory at IIT-Guwahati.

The animal or pre-clinical trials are yet to begin, but Gandhi said it is important to get things right. "There will be a room for multiple vaccines in the market. It's important to do the job correctly," he said.

Similarly, a team of researchers, led by IIT-Bombay alumnus Prabhudatta Kundu, is developing a triple-antigen vaccine at Pandey Biotech. He has successfully identified three major antigens as a recombinant novel coronavirus vaccine candidate.

According to Kundu, unlike single-protein vaccines currently under trial across the world, Premas Biotech has adopted a three-pronged approach to develop multi-subunit vaccine. The triple-antigen Covid-19 vaccine candidate, PRAK-03202, has produced neutralising immune response in mice. Premas Biotech is now in talks with regulatory authorities for the next phase.


Its animal study of the SARS-CoV-2 vaccine candidate comprised 50 mice, divided into 10 groups of five, and 20 mice in a group of PRAK-03202. The vaccine candidate was generally well tolerated and safe at all doses, with



SOME OF THE VACCINE CANDIDATES IN INDIA


Company	Vaccine technology	Status
Biological E	Protein subunit	Pre-clinical
Indian Immunologicals	Liver attenuated	Pre-clinical
Myxas	Subunit based	Pre-clinical, human trials by April 2021
Auro Vaccines	Viral vector	Pre-clinical
Genovax Biopharma	Next-generation mRNA	Pre-clinical
Premas Biotech	Triple antigen	Pre-clinical
Neuberg Supratech	Recombinant virus vector	Pre-clinical
Hester Biosciences + IITG	Recombinant virus vector	Pre-clinical
CMC, Vellore	Liquid encapsulated mRNA	Pre-clinical

INDIA HAS 40% OF GLOBAL VACCINE CAPACITY



Source: Govt. Vaccine Alliance, WHO, press reports, Bernstein analysis

CAPACITIES (FY20)



Source: Company reports, press reports, Bernstein analysis

no adverse events reported. It was safe even at higher doses and generated a robust immune response against all three SARS-CoV-2 antigens.

The company, which has its specialisation in protein therapeutics, is willing to go slow with the trials since it wants to ensure efficacy of the vaccine candidate.

"We are in talks with regulatory authorities to discuss Phase-I trials. We have put up the case to them on how our vaccine can be scaled up quickly since large-scale manufacturing of yeast is easily possible. In the next couple of months, we should be conducting Phase-I. We wanted to make sure we do it well first time rather than hurry," said Kundu.

Premas claimed its production cycle of one week is the fastest among the world for antigen-based vaccine. The company said it can make 20-30 million doses in a week since the system based of yeast is highly scalable.

On the other hand, Gujarat government arm Gujarat Biotechnology Research Centre (GBRC) signed an agreement with Neuberg Supratech Reference Laboratory, Ahmedabad, a unit of Neuberg Diagnostics, a start-up in the

pathlab chain segment.

According to the agreement, they would develop Covid-19 recombinant vaccine and diagnostics. As part of the agreement, Neuberg Supratech has been looking for immune markers for Covid-19 positive patients by using several of its in-house high throughput sequencing machines. The firm declined to respond.

These smaller players are likely to play a key role when it comes to scaling up manufacturing of the successful candidate. Gandhi said his Nepal plant is operating at 25 per cent capacity, and the company can easily use it to contract manufacture any candidate that emerges successful first. "We can also enhance the capacity easily without much investment. We will definitely chip in to scale up India's manufacturing of the Covid-19 vaccine," said Gandhi.

The large players have already indicated that they are repurposing their existing capacities to make way for the Covid-19 vaccine. Some like Serum Institute are using capacities for Covid-19 vaccines, while others like Indian Immunologicals plan to use multi-product facilities to make additional volumes.

Biocon's skin drug sales surge despite limited Covid-19 study

Firm hopes the sales of itolizumab will pick up as it enters Ph-4 trials

SOHINI DAS & SAMHEEN AHMAD
Mumbai/Bengaluru, 5 October

Biocon's repurposed psoriasis drug itolizumab has seen an sevenfold jump in sales after it got an emergency use authorisation for Covid-19 treatment. The drug, however, is yet to be a part of the clinical management protocol of the health ministry for treatment of Covid-19, which implies that the government has not yet recommended it as an effective treatment.

With Phase-4 clinical trials on, sales may see a further uptick if the data supports it helps Covid-19 patients, said experts. The data from market research firm AIOCD AWACS showed that volumes shot up seven times in August (350 units) from just 50 units in July when it received the approval. In June, the drug did not show sales.

In India, itolizumab, known by the brand name Altuzam, has been priced at ₹8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to

Bharat Biotech to use adjuvant for Covaxin

Bharat Biotech will use adjuvant from Kansas-based ViroVax for its Covaxin. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine. It may be added to a vaccine to produce more antibodies and longer lasting immunity, thus minimising the dose of antigen needed. Bharat Biotech is conducting Phase-2 clinical trials in healthy volunteers for Covaxin. SOHINI DAS

₹32,000. In a few cases, a patient might need two more vials.

To repurpose the drug for Covid-19, the previous trial was done on a cohort of 30 patients suffering from moderate to severe acute respiratory disorder syndrome due to Covid-19. Of them, 20 received itolizumab and 10 received standard care. The 20 who were administered itolizumab

recovered fully, the firm said. Three of the 10 patients under standard care died.

After many experts pointed out that the study was conducted on limited number of patients, Biocon has started a Phase-4 post-marketing surveillance of the drug on a pool of 300 patients that will take a couple of months to complete.


A Phase-4 study is a follow-up on real world evidence on the efficacy and safety of a drug. "When we did a proof of concept study, we got the emergency use authorisation because it is already an approved drug and has a lot of safety data," said Kiran Mazumdar-Shaw, executive chairman, Biocon.

Satyanarayana Mysore, head of department of interventional pulmonology, Manipal Hospitals, who used the drug on Covid-19 patients said the use of the drug would rise if more supporting data emerges. Mysore used the drug on two patients when Roche's tocilizumab was not available. "Both responded well. But two is a small number," Mysore said.

Shaw had earlier said Biocon sees itolizumab as a blockbuster opportunity for the firm and has been working towards ramping up its capacity.

RIDING COVID-19 WAVE, PEVC INVESTMENTS CROSS \$1 BILLION

Private equity (PE) and venture capital (VC) investments in pharmaceutical companies have increased by over 3.5 times in 2020 and crossed \$1 billion for the first time to touch \$1.69 billion during January to September period, compared to \$368 million a year ago. Fund managers said investors remain positive on pharma manufacturing activity in India, which has strengthened during the pandemic on account of restrictions from Chinese pharma imports. Last year, the sector attracted \$825 million across 18 deals, according to Venture Intelligence. Some of the deals reported in 2020 include Carlyle's \$490 million investment in Piramal Pharma, KKR's \$64 million investment in JB Chemicals, and Carlyle's \$210 million investment in Sequent Scientific. TE NAJASHAHAN



PEVC INFLOWS IN DRUG FIRMS (2017-2020 YTD)

Year	Deals*	Amount (\$m)
Jan-Sep 2020	19	1,692
2019	18	825
Jan-Sep 2019	10	358
2018	20	452
Jan-Sep 2018	15	768
2017	18	395
Jan-Sep 2017	14	270

*Note: Pharmaceutical companies include drug R&D, manufacturing & services, commercial, OTC and CMO, if involved

SOURCE: VENTURE INTELLIGENCE

TOP PEVC INVESTMENTS (2017-2020 YTD)

Company	Investor	Amount (\$m)	Date
Piramal Pharma	Carlyle	490	Jun '20
JB Chemicals	KKR	64	Jul '20
Sequent Scientific	Carlyle	210	May '20
Intas Pharmaceuticals	Chrysalis	120	Feb '20
RA Chem Pharma	Advent International	128	Jul '20

SOURCE: VENTURE INTELLIGENCE

TATA sky Broadband

Dear Customer we at Tata Sky Broadband Private Limited (TSBB) are committed to providing you with the best possible service. For any reason if you are not satisfied with our services or have any queries, you may contact us at under:

Write to us at: care@tatskybroadband.com

TSBB Customer Care Number: 1-800-267-6771 (toll free) is available 24 hours on all days of the week. Please remember to take the docket/complaint number after your complaint is registered by the customer care executive.

If you are not satisfied with our response or your complaint remains unresolved, you may make an appeal to the Appellate Authority, Mr. Surjeet, Maharashtra at appellateauthority@tatskyb.com on 09821663399 from 9:30 am to 6:30 pm (Monday to Friday).

To access the status of your complaint in the Web-based Complaint Monitoring System, log on to <https://myaccount.tatskybroadband.com/SelfCare/>

For all other terms & conditions, please visit www.tatskybroadband.com

Registered Office: Unit 306, 3rd Floor, Windsor, Off C.S.T. Road, Kalina, Santacruz (East), Mumbai 400008.
CIN: U62040MH2012PTC0267809
www.tatskybroadband.com

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

TSBB is a Tata Group Company. All trademarks and intellectual property rights are reserved by Tata Group. All rights reserved.

YUKO बैंक UCO BANK

(Govt. of India Undertaking)
Head Office - 8, Department of Information Technology
3 & 4, DD Block, Sector - 1, Salt Lake, Kolkata-700064

NOTICE INVITING TENDER

UCO Bank invites Request (RFP) for Selection of Vendor for providing Annual Technical Support (ATS) Software Assurance (SA) for Microsoft Product.

2. Request for Proposal (RFP) for Supply, Installation and Maintenance of Hardware, Operating Systems and Database Licenses for various Projects/Applications.

Interested vendors are requested to visit the website www.ucobank.com for details and to download the RFP.

Date: 06.10.2020

Honours Your Trust

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

UCO Bank

Balaxi Ventures Limited

Registered Office: Plot No. 409, H.No. 9-2-365, Maps Towers, 3rd Floor,
Rajeev, Road No. 81, Balaji Nagar, Hyderabad, India - 500099.
CIN: L25191TG1942PLC151558

Phone: +91 40 23553501 Email: info@balaxiventures.in Website: www.balaxiventures.in

NOTICE

Notice is hereby given pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 that a meeting of the Board of Directors of the Company will be held on Monday, 12th October, 2020 at the Registered Office of the Company to inter-alia, consider, approve and take on record the Un-Audited Financial Results for the Quarter and Half Year ended 30th September, 2020.

This information will be made available on the Company's website www.balaxiventures.in and on the website of stock exchange on www.nseindia.com

Date: 05th October, 2020

Place: Hyderabad

For, Balaxi Ventures Limited

Ashish Maheshwari

Managing Director

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

Balaxi Ventures Limited

HINDALCO INDUSTRIES LIMITED

Registered Office: "New Centre", 1st Floor, 1st Stage, Marolli Nagar, Andheri East, Mumbai-400 059.
CIN: L24240MH2012PLC00112